Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once … – Dove Medical Press

William B Saunders,¹ Hiep Nguyen,² Iftekhar Kalsekar²

¹Department of People Good health Sciences, College of Good health and Human Services, The University of North Carolina at Charlotte, Charlotte, NC, ²AstraZeneca, Fort Washington, PA, USA

Aim: The glucagon-adore peptide-1 receptor agonists exenatide as soon as once a week (QW) and liraglutide as soon as day-to-day (QD) have actually shown improvements in glycemic results in patients along with form 2 diabetes mellitus in randomized medical trials. However, little is known concerning their real-globe comparative effectiveness. This retrospective cohort study maximized the Quintiles Electronic Clinical Tape-record database to evaluate the 6-month modification in glycated hemoglobin (A1C) for patients initiating exenatide QW or liraglutide QD.
Methods: Patients along with form 2 diabetes mellitus prescribed exenatide QW (n=664) or liraglutide QD (n=3,283) in between February 1, 2012 and Might 31, 2013 were identified. Baseline A1C measures were from 75 days prior to to 15 days after initiating exenatide QW or liraglutide QD, along with follow-up measures documented at 6 months (±45 days). Adjusted linear regression models compared the distinction in mean A1C change. A priori determined sensitivity analysis was executed in the subgroup of patients along with baseline A1C ≥7.0% and no prescription for insulin throughout the 12-month pre-index period.
Results: For exenatide QW and liraglutide QD, respectively, mean (SD) age of the main study cohort was 58.01 (10.97) and 58.12 (11.05) years, mean (SD) baseline A1C was 8.4% (1.6) and 8.4% (1.6), and 48.2% and 54.2% of patients were women. In adjusted models, modification in A1C did not differ in between exenatide QW and liraglutide QD throughout 6 months of follow-up. Outcomes were continual in the subgroup analyses.
Conclusion: In a real-globe setting, A1C similarly boosts in patients initiating exenatide QW or liraglutide QD.

Keywords: diabetes, exenatide, outcomes

This job is published and licensed by Dove Clinical Press Limited. The complete terms of this license are readily available at http://ift.tt/1X6Iw1k and integrate the Creative Commons Attribution – Non Commercial (unported, v3.0) License. By accessing the job you hereby accept the Terms. Non-commercial uses of the job are allowed devoid of any sort of further permission from Dove Clinical Press Limited, given the job is appropriately attributed. For permission for commercial usage of this work, please observe paragraphs 4.2 and 5 of our Terms.

Download Information [PDF]